【环球网财经综合报道】8月以来，A股公司赴港上市步伐明显加快。据不完全统计，已有近20家A股上市公司宣布拟筹划赴港上市，立讯精密、胜宏科技、 军信股份、星环科技等企业已正式向港交所递交H股发行上市申请。这些企业中不乏细分行业头部企业，如立讯精密、胜宏科技的A股总市值均已突破千亿 元。 8月24日晚，格林美发布公告称，董事会同意公司发行H股股票，并在港交所主板挂牌上市。此前，华勤技术、科兴制药等A股上市公司于8月22日晚间披露 了赴港上市计划。企业普遍表示，拓展国际化战略、优化海外业务布局、提升品牌知名度、增强境外融资能力及综合竞争力是赴港上市的主要动因。 港交所于8月4日生效的新规优化了首次公开招股市场定价及公开市场规则，既提升了发行人融资灵活性，也加强了对投资者的保护。业内认为，这将进一步 推动A股公司赴港上市。 从行业分布来看，近期筹划赴港上市的A股公司覆盖电子、机械设备、医药生物、食品饮料、化工、传媒等多个领域。其中，电子行业企业最为集中，华勤 技术、芯海科技、露笑科技、极米科技、晶合集成、普源精电等均计划赴港上市；医药生物领域有科兴制药、可孚医疗两家公司披露相关计划。此外，计算 机行业的卓创资讯与万兴 ...

Core Viewpoint - The company plans to complete its H-share issuance and listing as part of its "innovation + internationalization" strategy, marking its first external equity financing since its A-share listing in 2000 [2][3]. Group 1: Timing and Market Context - The timeline for the company's Hong Kong listing has been rapid, with key milestones achieved within five months, reflecting a strategic response to the evolving pharmaceutical regulatory and market landscape in China [3]. - The international capital market's increasing acceptance of Chinese innovative drugs is a significant factor in the company's decision to list in Hong Kong, which serves as a bridge to global markets [5]. - The listing will provide the company with flexible financing tools to support its international expansion efforts [5]. Group 2: Strategic Goals and Achievements - The listing is aimed at expanding the company's overseas business and enhancing international research collaborations, thereby achieving breakthroughs in foreign markets [6]. - The current trend of high-quality Chinese companies listing in Hong Kong is expected to attract capital returning from a weakening US dollar [7]. - The company has made significant strides in its global presence, with products registered in over 40 countries and regions, and has established 14 global R&D centers [8]. Group 3: Financial Performance and Future Plans - The company reported a revenue of 27.985 billion yuan in 2024, a year-on-year increase of 22.6%, and a net profit of 6.337 billion yuan, up 47.3% [11]. - The funds raised from the listing will primarily be used for innovative drug development, international expansion, and operational capital, aiming to enhance its market presence [11]. - The company is positioned to transition from a domestic leader in innovative drugs to a global pharmaceutical player, with the Hong Kong listing seen as a starting point rather than an endpoint [11].